Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 18/20 | 0.71 |
| ▸ | EGFR | P00533 | 14/20 | 0.71 |
| ▸ | ABL1 | P00519 | 11/20 | 0.71 |
| ▸ | ABL2 | P42684 | 11/20 | 0.71 |
| ▸ | CDK1 | P06493 | 6/20 | 0.71 |
| ▸ | KDR | P35968 | 5/20 | 0.71 |
| ▸ | CSK | P41240 | 2/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL399404 | 0.84 | SRC (0.51) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL31061695 | 0.83 | SRC (1.00) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL5936176 | 0.83 | SRC (1.00) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL399678 | 0.82 | SRC (0.49) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL400054 | 0.81 | SRC (0.47) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL401860 | 0.80 | SRC (0.47) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL7845704 | 0.78 | SRC (0.84) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL400111 | 0.78 | SRC (0.46) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL402145 | 0.78 | SRC (0.45) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL400407 | 0.78 | SRC (0.48) | SRCEGFRABL1ABL2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491923-A2 | Combinations of therapeutic agents for treating cancer | Novartis AG (CH) | 2012-08-29 | — | — | EP | claimed |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2010-10-28 | — | — | US | claimed |
| US-20100069458-A1 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | claimed |
| EP-2120900-A2 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER | Novartis AG (CH) | 2009-11-25 | — | — | EP | claimed |
| WO-2008100985-A2 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2008-08-21 | — | — | WO | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | BROWN DENNIS (US) | 2025-01-14 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-06-08 | — | — | US | disclosed |
| CN-1531538-A | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-D) pyrimidie derivatives | ��˹��ŵ�� | 2004-09-22 | — | — | CN | disclosed |
| US-20040180911-A1 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
| US-20040180911-A1 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
| US-20040180911-A1 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
| EP-1390369-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2004-02-25 | — | — | EP | disclosed |
| EP-1390369-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002092599-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO (2,3-D) PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002092599-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO (2,3-D) PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | SRC 1968/4885EGFR 1496/4885ABL1 785/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | SRC 1968/4885EGFR 1496/4885ABL1 785/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | SRC 1968/4885EGFR 1496/4885ABL1 785/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | SRC 1586/4885EGFR 3481/4885ABL1 746/4885 |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | ANXA5, BAX, ANXA6 | SRC 2088/4885EGFR 1372/4885ABL1 3228/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | SRC 1968/4885EGFR 1496/4885ABL1 785/4885 |
| US-20100069458-A1 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER | MCL1, BAD, LPXN | SRC 3382/4885EGFR 554/4885ABL1 468/4885 |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DDOST, DAD1, PHGDH | SRC 4123/4885EGFR 2453/4885ABL1 4855/4885 |
| US-20040180911-A1 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | TYMP, DPYD, TYMS | SRC 2626/4885EGFR 2559/4885ABL1 1490/4885 |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | HEXD, DDOST, PAICS | SRC 3186/4885EGFR 2685/4885ABL1 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.